0001829126-23-004053.txt : 20230609 0001829126-23-004053.hdr.sgml : 20230609 20230609163515 ACCESSION NUMBER: 0001829126-23-004053 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230606 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leider Harry L. CENTRAL INDEX KEY: 0001888273 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-55008 FILM NUMBER: 231005895 MAIL ADDRESS: STREET 1: C/O GELESIS, INC. STREET 2: 501 BOYLSTON STREET, SUITE 6102 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organicell Regenerative Medicine, Inc. CENTRAL INDEX KEY: 0001557376 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474180540 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 BUSINESS ADDRESS: STREET 1: 3321 COLLEGE AVENUE STREET 2: SUITE 246 CITY: DAVIE STATE: FL ZIP: 33314 BUSINESS PHONE: 888-963-7881 MAIL ADDRESS: STREET 1: 3321 COLLEGE AVENUE STREET 2: SUITE 246 CITY: DAVIE STATE: FL ZIP: 33314 FORMER COMPANY: FORMER CONFORMED NAME: Biotech Products Services & Research, Inc. DATE OF NAME CHANGE: 20150917 FORMER COMPANY: FORMER CONFORMED NAME: BESPOKE TRICYCLES INC DATE OF NAME CHANGE: 20120831 3 1 ownership.xml FORM 3 X0206 3 2023-06-06 0 0001557376 Organicell Regenerative Medicine, Inc. OCEL 0001888273 Leider Harry L. 3321 COLLEGE AVENUE SUITE 246 DAVIE FL 33314 1 1 0 0 CEO and Director Options to Purchase Common Stock 0.012 2023-09-06 2028-06-06 Common Stock, par value $0.001 per share 57000000 D Represents an option to purchase common stock granted to the Reporting Person on June 6, 2023 under the issuer's Equity Incentive Plan (the "Plan"). The option vests in equal quarterly installments over a three-year period from the date of grant, is contingent upon the Reporting Person's continued employment by the issuer and is otherwise subject to the terms and conditions of the Plan. In the event of a "change in control" or the achievement of certain milestones, vesting of the option may be accelerated. /s/ Harry Leider 2023-06-09